Surgery Partners, Inc. (SGRY)
NASDAQ: SGRY · Real-Time Price · USD
21.26
+0.25 (1.19%)
At close: Jul 25, 2025, 4:00 PM
21.26
0.00 (0.00%)
After-hours: Jul 25, 2025, 4:20 PM EDT
Surgery Partners Stock Forecast
Stock Price Forecast
The 9 analysts that cover Surgery Partners stock have a consensus rating of "Buy" and an average price target of $34, which forecasts a 59.92% increase in the stock price over the next year. The lowest target is $24 and the highest is $43.
Price Target: $34 (+59.92%)
Analyst Consensus: Buy
* Price targets were last updated on May 27, 2025.
Analyst Ratings
The average analyst rating for Surgery Partners stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Hold Maintains $25 → $24 | Hold | Maintains | $25 → $24 | +12.89% | May 27, 2025 |
| Benchmark | Benchmark | Strong Buy Reiterates $35 | Strong Buy | Reiterates | $35 | +64.63% | Apr 21, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $35 | Buy | Reiterates | $35 | +64.63% | Mar 25, 2025 |
| Macquarie | Macquarie | Buy Maintains $34 → $33 | Buy | Maintains | $34 → $33 | +55.22% | Mar 11, 2025 |
| JP Morgan | JP Morgan | Hold Maintains $38 → $28 | Hold | Maintains | $38 → $28 | +31.70% | Dec 3, 2024 |
Financial Forecast
Revenue This Year
3.44B
from 3.11B
Increased by 10.55%
Revenue Next Year
3.76B
from 3.44B
Increased by 9.21%
EPS This Year
0.90
from -1.33
EPS Next Year
1.13
from 0.90
Increased by 26.17%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.6B | 4.0B | 4.5B | ||
| Avg | 3.4B | 3.8B | 4.1B | ||
| Low | 3.3B | 3.5B | 3.9B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 14.6% | 16.0% | 19.2% | ||
| Avg | 10.6% | 9.2% | 10.2% | ||
| Low | 4.5% | 2.7% | 3.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.27 | 1.79 | 1.85 | ||
| Avg | 0.90 | 1.13 | 1.37 | ||
| Low | 0.46 | 0.69 | 1.03 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 98.8% | 63.1% | ||
| Avg | - | 26.2% | 21.1% | ||
| Low | - | -23.6% | -9.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.